Guatemala vs Kyrgyzstan: The number of people with susceptibility test result for rifampicin
Guatemala
2,022
in 2021
Kyrgyzstan
1,932
in 2021
Guatemala rank
46th
Kyrgyzstan rank
49th
The number of people with susceptibility test result for rifampicin over time
- Guatemala
- Kyrgyzstan
How they compare
Guatemala currently reports 2,022 against 1,932 in Kyrgyzstan, a difference of 90.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Kyrgyzstan ahead.
Guatemala ranks 46th and Kyrgyzstan ranks 49th of 155 countries.
Kyrgyzstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guatemala | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,126 | 2,316 | 1,190 | Kyrgyzstan |
| 2020s | 1,352 | 1,836 | 484.5 | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Guatemala or Kyrgyzstan?
- Guatemala, at 2,022 against 1,932 in Kyrgyzstan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Guatemala and Kyrgyzstan?
- 90, with Guatemala ahead.
- How many years of comparable data are there for Guatemala and Kyrgyzstan?
- 5 years are reported by both, from 2017 to 2021.
- How do Guatemala and Kyrgyzstan rank globally for the number of people with susceptibility test result for rifampicin?
- Guatemala ranks 46th and Kyrgyzstan ranks 49th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.